知名上市械企，被证监会调查！

Core Viewpoint - Shenzhen Yahui Long Biotechnology Co., Ltd. (stock code: 688575) is under investigation by the China Securities Regulatory Commission (CSRC) for misleading statements in information disclosure [1][4]. Company Overview - Yahui Long was established in 2008 and is headquartered in Shenzhen, focusing on the in vitro diagnostics (IVD) sector [4][5]. - The company specializes in the research, production, and sales of chemiluminescent immunodiagnostic reagents, biochemical diagnostic reagents, and related instruments, holding a significant market share in autoimmune disease detection [4][5]. Investigation Details - The investigation stems from a voluntary disclosure made by Yahui Long on January 6, 2026, regarding a strategic cooperation agreement with Shenzhen Brain Machine Star Chain Technology Co., Ltd. [5][6]. - Following the announcement, Yahui Long's stock price rose by 6.52% on January 7, with trading volume increasing by 299% compared to the previous day [2][5]. Regulatory Response - The Shanghai Stock Exchange issued an inquiry letter to Yahui Long, requesting verification of the technology path, product status, and research progress of Brain Machine Star Chain [2][6]. - Yahui Long later acknowledged that Brain Machine Star Chain is currently focused only on non-invasive technology and has no invasive technology layout, with some products still in early research or preclinical stages [2][5]. Compliance Issues - The Shanghai Stock Exchange issued a regulatory warning to Yahui Long's then Secretary of the Board, Wang Mingyang, for inconsistent disclosures and insufficient risk warnings [6]. - The CSRC's investigation aims to ensure the healthy development of the market following the company's failure to adequately disclose cooperation feasibility and uncertainties [6].